Stoke Therapeutics (STOK) Other Operating Expenses (2019)
Stoke Therapeutics (STOK) posted quarterly Other Operating Expenses of $152.4 million for Q4 2025, up 439.1% quarter-over-quarter from -$44.9 million in Q2 2025.
Powered by 
Analysis
Stoke Therapeutics (STOK) Other Operating Expenses (2019) Analysis & Trends
Stoke Therapeutics' Other Operating Expenses history runs 4 years deep, the most recent figure standing at $152.4 million for Q4 2025.
- In Q4 2025, Other Operating Expenses changed N/A year-over-year to $152.4 million; the TTM figure through Mar 2026 stood at $107.4 million (up 379.27% YoY), while the FY2023 annual figure was -$133.6 million, changed N/A from the prior year.
- Other Operating Expenses for Q4 2025 stood at $152.4 million, up from -$44.9 million in the prior quarter.
- The five-year high for Other Operating Expenses was $152.4 million in Q4 2025, with the low at -$133.6 million in Q4 2023.
- The 3-year median for Other Operating Expenses is -$41.7 million (2024), against an average of -$16.2 million.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Stoke Therapeutics | 1.96 Bn | 1.66 Bn | - |